The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.
MindMed’s stock soars 58% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
Read Next
- Draft Trump order would make sweeping State Department changes
- 7 habits of people who create connection in every conversation
- Trump ‘flouting the courts’ in Abrego Garcia case
- Yen, Brazilian Real, 5-Year Bonds & WTI Crude Oil lead Weekly Positions :: InvestMacro
- Vance to visit India for bilateral talks on trade and economic ties
- FX week in review: Scope and IC Markets MENA heads, Crypto exchanges adding traditional trading
- 7 things confident people never feel the need to explain
